Bearish
Heron Therapeutics (HRTX) is facing a challenging long-term repositioning strategy after undergoing a 1-for-25 reverse stock split in 2024 to meet Nas...
Bearish
A U.S. District Court has ruled two of Heron Therapeutics' CINVANTI patents invalid in a dispute with Azurity. Heron Therapeutics (HRTX) announced its...
Neutral
Heron Therapeutics announced that the U.S. District Court for the District of Delaware ruled its CINVANTI® patents invalid in a dispute with Azurity P...